Radiant Bio has developed a modular multi-valent and multi-specific platform utilizing a human self-multimerizing scaffold, apoferritin, to enhance antibody fragments. This technology enables the creation of potent multi-functional biologics aimed at treating difficult diseases such as cancer, autoimmune disorders, and infections by leveraging stronger binding power and multi-specificity.
Funding
$43.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, such as cancer, autoimmune disorders, and infections, are difficult to treat due to limited binding power and specificity of existing biologics. Current therapeutic approaches often struggle to effectively target multiple disease pathways simultaneously.
Solution
Radiant Bio has developed the Multabody platform, a modular, multi-valent, and multi-specific technology that enhances antibody fragments using a human self-multimerizing scaffold, apoferritin. This platform enables the creation of potent multi-functional biologics capable of addressing complex diseases. By exploiting avidity—stronger binding power—coupled with multi-specificity, Multabodies deliver next-generation therapeutics with improved developability and pharmacokinetics. The platform's modularity allows for the creation of biologics that can target multiple disease pathways simultaneously, potentially unlocking cures for patients.
Target Audience
Radiant Bio's primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for cancer, autoimmune disorders, and infectious diseases.
Features
- Utilizes a human apoferritin scaffold for self-multimerization of antibody fragments.
- Enables multi-valent and multi-specific binding for enhanced therapeutic efficacy.
- Modular design allows for rapid development of biologics targeting multiple disease pathways.
- Antibody framework ensures antibody-like developability and pharmacokinetics.